ImmunoScape

Highly selective T cell engagers to expand T cell therapies in vivo.

ImmunoScape offers partnering opportunities centered on its Seed-and-Boost approach. Its platform technology supports development of T cell therapies across targets, patient backgrounds and cell modalities.

The 2020 BIO International Convention moved to a virtual format called BIO Digital, offering biotech industry participants partnering opportunities and educational resources.

The webinar covers how high-dimensional mass cytometry and combinatorial peptide-HLA tetramers can profile T cell responses to infections and identify potentially protective epitopes for vaccine development.

The webinar covers ImmunoScape’s TargetScape assay for identifying and profiling immune responses, with an overview of the technology and case studies. Presenter Dr. Yannick Simoni is ImmunoScape’s Associate Director of Technology Development.

The webinar covers how ImmunoScape used mass cytometry to compare immune cell profiles across patients and timepoints and correlate them with post-radiotherapy tumor responses. It reports an expansion of activated Ki-67+ CD8+ T cells.

The exclusive collaboration and license agreement focuses on a “Seed-and-Boost” T cell therapy approach using the CUE-100 series of Immuno-STATs to expand and activate infused TCR-engineered T cells in vivo.

ImmunoScape Pte. Ltd. announced a strategic investment from Leonardo DiCaprio and an MOU with an NCI-designated Comprehensive Cancer Center in the United States.

ImmunoScape announced the appointment of Peter, a biotech industry veteran with two decades of clinical development, manufacturing and technical operations leadership, to guide its Seed and Boost platform toward the clinic.

ImmunoScape presented preclinical data at the 2026 AACR Annual Meeting on its Seed and Boost platform for solid tumor immunotherapy. The study reported TCR-T cell expansion, durable antitumor activity and 100% survival in a high-tumor-burden ovarian cancer model.

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology

ImmuniScape discovers and develops novel TCR-based therapeutics against solid tumors